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Summary. Background: The incidence of venous thrombosis
(VT) for cancer patients is increased compared with patients
without cancer, but estimations of the incidence for diﬀerent
types of cancer have rarely been made because of the low
incidence of various types of cancer. Large registries oﬀer an
opportunity to study the risk of VT in large cohorts of
cancer patients, which is essential in decisions on prophy-
lactic anti-coagulant treatment. Methods: This cohort study
estimates the incidence of VT in cancer patients by using record
linkage of a Cancer Registry and an Anticoagulation Clinic
database in the Netherlands. Cumulative incidences in patients
with diﬀerent types of malignancies were estimated. We
calculated relative risks (RRs) in relation to the presence of
distantmetastases and treatment. Results:Tumors of the bone,
ovary, brain, and pancreas are associated with the highest
incidence of VT (37.7, 32.6, 32.1, and 22.7/1000/0.5 year).
Patients with distant metastases had a 1.9-fold increased risk
[RRadj: 1.9; 95% conﬁdence interval (CI): 1.6–2.3]. Chemo-
therapy leads to a 2.2-fold increased risk (RRadj: 2.2; 95% CI:
1.8–2.7) and hormonal therapy leads to a 1.6-fold increased risk
(RRadj: 1.6; 95%CI: 1.3–2.1) compared with patients not using
these treatment modalities. Patients with radiotherapy or
surgery did not have an increased risk. Conclusions: We
compared the overall incidences of VT in the ﬁrst half year in
our study to the risk of major bleeding as described in the
literature. For patients with distantmetastases, for several types
of cancer, prophylactic anti-thrombotic treatment could be
beneﬁcial.
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Introduction
Patients with cancer have an increased risk of deep vein
thrombosis (DVT) comparedwith patientswithout cancer [1,2].
This increased riskvaries betweendifferent typesof cancer [2–4].
In a recent case–control study, the highest risk was associated
with lungcancer [odds ratio (OR): 22.2; 95%conﬁdence interval
(CI): 3.6–136.1], hematological cancer (OR: 28.0; 95% CI:
4.0–199.7), and gastrointestinal cancer (OR: 20.3; 95% CI:
4.9–83.0) [2]. Cancers with a moderately increased risk were
ovarian cancer (OR: 3.1; 95%CI: 0.6–15.3) and prostate cancer
(OR: 2.2; 95%CI: 0.9–5.4). Because of a relatively low incidence
of various types of cancer, large cohort studies are needed to
accurately estimate the incidence of venous thrombosis (VT) in
cancer with a low incidence. For clinical practice, knowledge of
the incidence of VT in cancer patients is helpful with regard to
making decisions about prophylactic antithrombotic treatment.
Database linkage has been proved to be a powerful tool in
epidemiological studies concerning the incidence of cancer after
VT. Two Scandinavian studies linked cohorts of patients with
VT deﬁned fromNational Registries of Patients with data from
National Cancer Registries [5,6]. Likewise, large cohorts of
different types of malignancy can be deﬁned from large
databases, and consequently be linked to databases with
information about VT incidence. An American study using a
Medicare database estimated the incidence of VT in cancer
patients in the ﬁrst 6 months after cancer diagnosis, by linking
hospital discharge data from different periods [7]. Tumors of
the ovary, brain, and pancreas had the strongest association
with VT in the Scandinavian studies as well as the American
study. Although database linkage is very effective, the reliab-
ility of the results is dependent on the quality of the registers
used. The health event has to lead to registration and details
such as diagnosis or identifying variables have to be recorded
correctly.
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The following cohort study is based on patient records from
the CancerRegistry in themid-western part of theNetherlands,
an urbanized area around the cities of Leiden and The Hague.
Linkage with the database of two Anticoagulation Clinics in
the same area is performed with the aim to ﬁnd incident
symptomatic cases of DVT. After performing a validation
study of the linkage procedure, we estimated the incidence of
DVT in patients with different types of malignancies before as
well as after the cancer diagnosis. Additionally, we studied the
effect of distant metastases, surgery, chemotherapy, and
radiotherapy on the risk.
Methods
The study cohort was deﬁned as the incident cancer cases
from 1986 to December 2002 entered in the population-
based Cancer Registry of the Comprehensive Cancer Center
West in the western part of the Netherlands, Leiden. This
Cancer Registry is one of the nine Dutch regional cancer
registries and covers 10% of the Dutch population
(approximately 1.6 million people). It has been operating
since 1986. Tumor data are abstracted from pathology
reports and medical records of hospital admissions. From
1989 the coverage is more than 98% [8]. From the Cancer
Registry we obtained demographic data of the patients,
information about the type of tumor, date of tumor
diagnosis, and type of initial therapy. We selected patients
from 1986 to December 2002 who were living in the
catchment area of the anticoagulation clinics of Leiden and
The Hague at the time of cancer diagnosis. Records of these
patients were linked to the database of the anticoagulation
clinics of The Hague and Leiden. In the Netherlands,
anticoagulation clinics manage the outpatient oral anticoag-
ulation treatment of all patients in a well-deﬁned geograph-
ical area. The data from the anticoagulation clinics of
Leiden and The Hague were used to deﬁne the incidence of
DVT in the cohort of cancer patients registered in the
Cancer Registry. From the Anticoagulation Clinic database
we used demographic data, indication for anticoagulant
therapy, and start and end date of anticoagulant therapy.
Validation study
To determine the optimal linkage procedure, we randomly
selected records of patients with and without cancer from the
anticoagulation clinic in Leiden. These patients underwent
anticoagulant therapy during the period 1990–1994. As a rule
but not consistently, a diagnosis of cancer is reported by
patients or their physicians to the anticoagulation clinics and
consequently registered in its database. Therefore, we could
select 166 patients who had cancer registered in the records of
the Anticoagulation Clinic. We also selected 456 patients
without cancer from the database of the anticoagulation clinics.
These 456 patients were also enrolled in the Multiple Environ-
mental and Genetic Assessment of risk factors for venous
thrombosis study (MEGA study) and had reported absence of
cancer [2]. Subsequently, we performed a record linkage with
the database of the Cancer Registry.
Personal identifying variables registered by the Cancer
Registry are ﬁrst four letters of the family name, ﬁrst initial,
birth date, sex, and postal code. These identiﬁers were also
available from the anticoagulation clinics. The variables
used for the record linkage were the ﬁrst four letters of the
family name and the birth date. The variables sex, ﬁrst
initial, and postal code were used for additional visual
evaluation of the links (i.e. records linking together). We
evaluated all links with equal birth date and equal ﬁrst four
letters of the family name with a systematic procedure using
the identiﬁers’ sex, ﬁrst initial, and postal code to improve
the speciﬁcity of our linkage procedure. Small differences in
either ﬁrst initial or postal code were accepted as a match.
A difference in sex was accepted in case all other variables
were equal or in case there was either a minor difference in
the postal code or a difference in ﬁrst initial.
In this validation, we used the data from the anticoagulation
clinics as standard, and calculated the sensitivity of linkage as
those registered with thrombosis and without cancer in the
anticoagulation clinics, who were linked as positive for cancer
in the Cancer Registry, and as speciﬁcity the patients with
thrombosis and without cancer according to the anticoagula-
tion clinics, who were not found in the Cancer Registry. Our
rationale for this approach was that the anticoagulation clinics
registry is based on medical treatment which is absolutely
required for VT, that we could obtain positive information on
the absence of cancer from an independent study, and that
another approach would have been difﬁcult to reconcile
without knowing the level of co-morbidity in the cancer
patients from the Cancer Registry.
Linkage of complete databases
After validating our linkage procedure, we performed a linkage
of the complete databases of the Cancer Registry (n ¼ 86 151
patients) and the anticoagulation clinics (n ¼ 157 482
patients), and calculated incidences of DVT 1 year before
cancer diagnosis and after cancer diagnosis per tumor type.
Information about use of anticoagulation therapy for other
reasons than VT was not used in the analyses.
Statistical analysis
In the absence of mortality data (the Cancer Registry includes
data only from the time of diagnosis and treatment) we
calculated the cumulative incidence over the ﬁrst 6 months
since cancer diagnosis as a measure of risk, in order to compare
between different types of cancer. In addition, the cumulative
incidence of VT since cancer diagnosis using the median
survival time per type of cancer was calculated. Median
survival time was obtained from the Eindhoven Cancer
Registry, comprising an area in the south of The Netherlands
[9]. The cumulative incidence is calculated as the proportion of
patients who developedVT in the speciﬁed time period after the
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cancer diagnosis. The denominator is the number of patients at
the start of the study.
To compare the effect of different forms of therapy, we
estimated relative risks (RRs) with 95% conﬁdence intervals
(CI). The risk of developing VT in the ﬁrst half year after
cancer diagnosis for patients undergoing chemotherapy,
radiotherapy, hormonal therapy or surgery as initial therapy,
was compared with the risk for patients without these
treatment modalities. Estimates of RRs are adjusted for
possible confounders, such as age and sex, by using Mantel–
Haenszel methods.
Among the cancer patients with a VT event in the 6 months
after cancer diagnosis, we estimated the cumulative incidence of
a recurrence in the six months after the thrombotic event and
compared it with the cumulative incidence in the 6th to 12th
month for patients without a thrombotic event in the ﬁrst
6 months by calculating an RR.
The analysis of incidence of VT in the presence of distant
metastases was performed in a subgroup of patients for whom
the absence or presence of distant metastases was known (n ¼
38 739 of a total of 66 329 patients). Calculations of incidences
were made with the STATA.8 software package.
Results
Validation study
All links with identical date of birth and identical ﬁrst four
letters of the family namewere reported. After visual inspection
of the other identiﬁers, all reported links were accepted as
matches as the other identiﬁers were also identical in the
reported links. Ten records out of 166 cancer patients could not
be matched. This yielded a sensitivity of 94.0%. Three of the 10
records of patients with cancer which could not ﬁnd a match in
the Cancer Registry were those of patients who came to live in
the area of the Comprehensive Cancer Center West after their
cancer diagnosis and were thus not registered. Three other
records did not ﬁnd a match in the Cancer Registry because of
the lack of complete coverage of the Cancer Registry. One
patient was registered with a different birth date in the
anticoagulation clinic database than in the Cancer Registry but
other identiﬁers were identical. Three other patients had an
identical birth date in both registries but spelling differences in
the name. Four of 456 records of patients without cancer found
a match in the Cancer Registry. These four matches were false-
positive links. Linkage occurred because of errors in the
spelling of the name or birth date.We calculated a speciﬁcity of
99.1%.Using additional evaluation of the other identiﬁers (sex,
ﬁrst initial, and postal code) in the validation set showed an
increase in speciﬁcity to 99.8%, and no decrease in sensitivity.
Linkage study
The linkage procedure was performed with the complete
databases, that is, not only patients with VT but also all
patients from the anticoagulation clinic were included. In total,
86 151 patients with cancer were registered in the Cancer
Registry database and 73 358 (Leiden) and 84 124 (The
Hague) patients in the database of the anticoagulation clinics.
We found 17 095 persons with a link. All positive links were
evaluated by comparing the identiﬁers – sex, initials, and postal
code. We decided 3.6% of positive links not to be a match.
In the anticoagulation clinic of Leiden, before 1990, the
indication code for anticoagulant therapy was removed from
the database when the patient received a new, different
indication. As a consequence, of 17 095 persons with a link
937 (5.5%) missed an indication for the therapy in the
earlier years. For the analysis, only matches with VT were
included.
Incidence of VT
A total of 66 329 patients with a ﬁrst, single tumor between
1986 and 2002 were included in the analysis. There were
33 253 women (50.1%) and 33 076 men (49.9%). We found
2149 patients with a VT in the year before the diagnosis of
cancer or after the diagnosis of cancer: 1240 patients with
DVT of the leg, 127 patients with DVT of the arm, 696
patients with a pulmonary embolism (PE), and 86 patients
with other forms of VT (VT in a rare location, such as
portal vein or mesenterial vein, or location not registered).
A recurrent VT event was found in 270 patients and three
patients had a third event.
Patients without a VT had amedian age of 66.6 years (25th–
75th percentile: 56.7–75.3) and patients with VT had a median
age of 68.5 (25th–75th percentile: 56.9–77.3). There were more
women among the patients with VT (52.0%) than among those
without VT (50.1%).
The overall cumulative incidence of VT in the ﬁrst
6 months was 12.3/1000 patients with cancer (95% CI:
11.5–13.0). Patients with tumors of the bone, ovary, brain,
and pancreas had the highest cumulative incidence of DVT
of the leg or arm or PE in the ﬁrst half year after diagnosis
of cancer (Table 1). The risk of a VT within 6 months after
this ﬁrst thrombotic event was 18.4/1000/0.5 year (11.1–30.0),
4.6-fold increased (RRadj: 4.6; 95% CI: 2.6–7.8) compared
with cancer patients who did not have a thrombotic event in
the 6 months after cancer diagnosis (3.9/1000/0.5 year; 95%
CI: 3.4–4.4). Recurrences were most often seen in patients
with leukemia (11/22), brain cancer (3/34) and cancer of the
bladder, ureter (2/29), and testis (1/5). There was no
difference for patients with or without distant metastases
(RRadj: 0.6; 95% CI: 0.2–2.5).
Patients with tumors of the ovary and pancreas also had a
high cumulative incidence of DVT in the year before the cancer
diagnosis. As the median survival time differs depending on
tumor type, cumulative incidences were also calculated per
median survival by tumor type (Table 2).
Overall, the incidence in the ﬁrst half year after cancer
diagnosis in patients with distant metastases was two times
higher (RRadj: 1.9; 95% CI: 1.6–2.3) than in patients
without distant metastases (20.5/1000/0.5 year; 95% CI:
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17.7–23.8 and 10.9/1000/0.5 year; 95% CI: 9.8–12.1, respect-
ively).
Risk associated with therapy
Patients who underwent chemotherapy as initial treatment had
an increased risk of VT. This effect was slightly stronger for
patients with distant metastases (RRadj: 2.4, 95% CI: 1.7–3.3
vs. RRadj: 2.0, 95% CI: 1.6–2.6) (Table 3). The overall RR for
chemotherapy adjusted for distant metastases, was 2.2 (RRadj
2.2, 95% CI: 1.8–2.7), compared with that for patients who
never underwent chemotherapy. There was no increased risk
for patients undergoing radiotherapy (RRadj: 0.7; 95%CI: 0.6–
0.9, compared with patients who did not undergo radiother-
apy) or surgery (RRadj 1.0; 95% CI: 0.8–1.2, compared to
patients who did not have surgery) as initial treatment. The
same analyses while adjusting treatment modalities for each
other did not alter theRRs.Hormone therapy for breast cancer
patients was associated with 1.8-fold increased risk for patients
without distant metastases and a 1.3-fold increased risk for
patients with distant metastases (Table 3) (overall RRadj: 1.6;
95% CI: 1.3–2.1). The risk associated with hormone treatment
in men with prostate cancer was only slightly increased
(Table 3) (RRadj: 1.2; 95% CI: 0.8–1.7) and independent from
the presence of distant metastases.
Discussion
For all types of malignancies combined, this cohort of 66 329
patients with cancer has a risk of VT of 12.3 per 1000 over
the ﬁrst 6 months after diagnosis (annualized: 24.6 per 1000
per year), which is clearly higher than the thrombosis risk in
the population (2 per 1000 per year) [10]. Patients with
tumors of the bone, ovary, brain, and pancreas had the
highest incidence of VT [6,7] (37.7, 32.6, 32.1, and 22.7/1000/
0.5 year, respectively). Patients with distant metastases and
those undergoing chemotherapy had a 2-fold increased risk
compared with those without metastases or not using
chemotherapy. Hormonal therapy led to a 1.5-fold increased
risk in breast cancer patients but not in prostate cancer
patients. For patients with radiotherapy or surgery, the risk
was not increased.
Patients who had their ﬁrst thrombosis within 6 months
after cancer diagnosis had a 4.8-fold increased risk of VT in the
Table 1 Cumulative incidence of venous thrombosis by tumor type, with or without distant metastases, in ﬁrst 6 months after cancer diagnosis, 1 year
before cancer diagnosis and recurrent venous thrombosis
Type of
malignancy
No. of
patients
No. of VTE
ﬁrst 0.5 year
Cumulative
incidence per
1000 patients
(95% CI)
Cumulative incidence
per 1000 patients with
distant metastases
(95% CI)
No. of VTE
in year before
cancer
Cumulative
incidence in year
before cancer per
1000 patients (95% CI)
Melanoma 2236 6 2.7 (1.2–6.0) – 3 1.3 (0.43–4.15)
Liver, bile ducts 970 7 7.2 (3.4–15.1) 7.9 (1.1–53.7) 5 5.2 (2.2–12.3)
Breast 10 566 84 8.0 (6.4–9.8) 24.8 (14.8–41.5) 15 1.4 (0.9–2.4)
Rectum, anus 2024 18 8.9 (5.6–14.1) 12.4 (4.0–37.6) 6 3.0 (1.3–6.6)
Prostate 6013 57 9.5 (7.3–12.3) 14.0 (8.6–22.7) 19 3.2 (2.0–5.0)
Testis 480 5 10.4 (4.3 (24.8) 40.8 (10.2–149.1) 0 –
Uterus 1431 15 10.5 (6.3–17.3) 79.0 (25.7–218.0) 6 4.2 (1.9–9.3)
Multiple myeloma 900 10 11.1 (6.0–20.5) – 0 –
Esophagus 1040 13 12.5 (7.3–21.4) 16.7 (6.3–43.6) 2 1.9 (0.5–7.7)
Kidney 1503 19 12.6 (8.1–19.7) – 5 3.3 (1.4–8.0)
Bladder + ureter 2250 29 12.9 (9.0–18.5) 30.6 (9.9–90.6) 9 4.0 (2.1–7.7)
Colon 6262 84 13.4 (10.8–16.6) 19.3 (12.5–29.7) 25 4.0 (2.7–5.9)
Leukemia 1594 22 13.8 (9.1–20.9) – 6 3.8 (1.7–8.4)
ALL 168 2 11.9 (3.0–46.3) – 1 6.0 (0.8–41.0)
CLL 524 9 17.2 (9.0–32.7) – 2 3.8 (1.0–15.1)
ANLL 532 9 16.9 (8.8–32.2) – 1 1.9 (0.3–13.2)
CML 165 1 6.1 (0.9–41.7) – 0 –
Other leukemias 205 1 4.9 (0.7–33.8) – 2 9.8 (2.4–38.2)
Lung 9336 129 13.8 (11.6–16.4) 17.9 (13.6–23.5) 39 4.2 (3.1–5.7)
Stomach 2337 36 15.4 (11.1–21.3) 10.5 (5.0–21.9) 12 5.1 (2.9–9.0)
Cervix uteri 866 14 16.2 (9.6–27.1) 34.5 (4.8–207.9) 1 1.2 (0.2–8.2)
Hodgkin’s lymphoma 417 7 16.8 (8.0–34.8) – 0 –
Non-Hodgkin’s
lymphoma
2470 49 19.8 (15.0–26.2) – 5 2.0 (0.8–4.9)
Pancreas 1674 38 22.7 (16.6–31.0) 51.6 (34.5–76.4) 10 6.0 (3.2–11.1)
Brain 1058 34 32.1 (23.1–44.6) – 1 1.0 (0.13–6.7)
Ovary 1444 47 32.6 (24.5–43.1) 49.8 (27.0–90.0) 13 9.0 (5.2–15.4)
Bone 159 6 37.7 (17.1–81.4) 62.5 (8.7–335.4) 0 –
Other 9299 86
Total 66 329 815 12.3 (11.5–13.0)
VTE, venous thrombotic event; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; ANLL, acute non-lymphocytic leukemia;
CML, chronic myeloid leukemia.
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6 months after this event compared with patients who had not
had a VT in the ﬁrst 6 months.
This cohort study estimates the incidence of DVT in
cancer patients by means of record linkage with a high
sensitivity and speciﬁcity of the linkage procedure. Using
large databases has the advantage of deﬁning large cohorts;
66 329 cancer patients having all types of cancer, with 2149
cases of VT. Tumors of the bone, ovary, brain, and pancreas
had the highest risk of thrombosis which is consistent with
other studies, as well as the high risk in the presence of
distant metastases [2,3,7,11]. Although we found that tumors
of the bone, ovary, brain, and pancreas have the highest risk
of thrombosis, most cases of VT were observed in patients
with cancer of the breast, prostate, lung and colon as these
types of cancer are more prevalent and have a longer survival
time (Table 2).
Tumors of the ovary, pancreas, lung, stomach, and hema-
tological malignancies had a high incidence of VT in the year
before the cancer diagnosis. This is consistent with a recently
published study [12].
At the Cancer Registry, initial therapy is registered without
dates of start and ﬁnish of treatment. Therefore, an accurate
association between therapy and VT over time could not be
estimated. Therapy not given as initial therapy but later during
the course of the disease and therefore not registered would
cause an underestimation of the risk. Therapy given after the
event of VT would cause an overestimation of the risk.
However, the estimated RRs in our study are still consistent
with other studies [1,3,11,13]. Surgery was not associated with
an increased risk in contrast with other studies. Although we
corrected for distant metastases, patients not undergoing
surgery might have had cancer in a more advanced stage of
disease, which would lead to an underestimation of the RR. In
a subgroup of patients we found that patients not undergoing
surgery have slightly more often lymphogenic metastases (data
not shown). An increased risk of recurrent thrombosis was also
found before, although incidences in these studies were higher
[14–16].
There are several drawbacks which can lead to uncertainty in
the estimated incidences. First, the incident cases of VT are not
completely captured in the database of the anticoagulation
clinics. In our study, in one of the anticoagulation clinics in the
earlier years, registration of indications was not complete and
we may have missed approximately 5% of the VT events.
Furthermore, patients with DVT who have not been treated
with oral anticoagulants are not registered in the anticoagula-
tion clinics, for example, the patients who died within 1 or
2 weeks after the VT incident. The percentage of short-term
case fatality rate of VT events in cancer patients is reported to
be approximately 12–25% [17,18].
Table 2 Incidence of venous thrombosis per type of malignancy during median survival time
Type of malignancy
No. of
patients
Median survival
(months)
No. of VTE in
median survival time
Cumulative incidence
per 1000 patients (95% CI)
Melanoma 2236 47.5 19 8.5 (5.4–13.3)
Liver, bile ducts 970 2 2 2.1 (0.5–8.2)
Breast 10 566 129 371 35.1 (31.8–38.8)
Rectum, anus 2024 45 41 20.3 (15.0–27.4)
Prostate 6013 42 168 27.9 (24.1–32.4)
Testis 480 289 9 18.8 (9.8–35.6)
Uterus 1431 189 55 38.4 (29.6–49.7)
Multiple myeloma 900 28 20 22.2 (14.4–34.2)
Esophagus 1040 8 16 15.4 (9.5–25.0)
Kidney 1503 39 36 24.0 (17.3–33.0)
Bladder + ureter 2250 33 61 27.1 (21.2–34.7)
Colon 6262 40 148 23.6 (20.2–27.7)
Leukemia 1594 – – –
ALL 168 11 2 11.9 (3.0–46.3)
CLL 524 53 16 30.5 (18.8–49.3)
ANLL 532 5 9 16.9 (8.8–32.2)
CML 165 31 3 18.2 (5.9–54.8)
Other leukemias 205 14 4 19.5 (7.3–50.8)
Lung 9336 8 152 16.3 (13.9–19.1)
Stomach 2337 8.5 40 17.1 (12.6–23.3)
Cervix uteri 866 99 27 31.2 (21.5–45.1)
Hodgkin’s lymphoma 417 220 15 36.0 (21.8–58.8)
Non-Hodgkin’s lymphoma 2470 35 71 28.7 (22.8–36.1)
Pancreas 1674 4 33 19.7 (14.1–27.6)
Brain 1058 6 34 32.1 (23.1–44.6)
Ovary 1444 30 65 45.0 (35.5–57.0)
Bone 159 67 9 56.6 (29.7–105.2)
Other 9299
Total 66 329
VTE, venous thrombotic event; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; ANLL, acute non-lymphocytic leukemia;
CML, chronic myeloid leukemia.
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Recently, we have studied the same question for lung and
pancreas cancer for hospital-based cohorts of patients with
these diagnoses [3,4]. In both studies the cumulative
incidences in the ﬁrst 6 months after cancer diagnosis
(74.3/1000, 95% CI: 68.3–80.3 for pancreatic cancer and
39.1/1000, 95% CI: 22.7–55.5 for lung cancer) were higher
than the incidence found in this study (22.7/1000, 95% CI:
16.6–31.0 for pancreatic cancer and 13.8/1000, 95% CI:
11.6–16.4 for lung cancer). For 50% of the patients with
pancreatic cancer and 10% of lung cancer patients, the
information was obtained from the medical records and was
not available in the anticoagulation clinic. These patients
were not treated with oral anticoagulants because of a poor
prognosis.
Secondly, there is the uncertainty of the linkage procedure.
To estimate the magnitude of this uncertainty, we performed a
validation study. Our cohort was deﬁned as the patients
registered at the Comprehensive Cancer Center West. The
linkage of the Cancer Registry and the Anticoagulation Clinic
database in the validation study is performed in an opposite
way, as described.We assume that the sensitivity and speciﬁcity
of our procedure in the main study will be the same as that
observed in the validation study – 94.0% and 99.1%,
respectively.
We observed an incomplete coverage of the Cancer Registry
in the validation study of 98.2%, but for the main study we are
interested in the coverage of the anticoagulation clinics. In the
Netherlands, all patients who use oral anticoagulants are
registered and treated in the anticoagulation clinic in their area,
so we expect the coverage to be high, as from the Cancer
Registry.
In the validation study, two (1.8%) of the cancer patients
changed address from outside the area of the Cancer
Registry to inside the area of the Cancer Registry. For the
main study, we were interested in the percentage of cancer
patients registered at the Cancer Registry, moving out of the
area of the anticoagulation clinic between their diagnosis of
cancer and a diagnosis of DVT because this will cause an
underestimation of the VT incidence. Presumably, this
percentage will be comparable with the 1.8% observed in
the validation study.
Primary prophylaxis of VT would be beneﬁcial if the
incidence of major bleeding while undergoing prophylactic
treatment, would be at least less than the incidence of VT
while not undergoing prophylactic treatment. This is a
precious balance, as patients with cancer are at increased
risk of hemorrhage while treated with anticoagulants. For
cancer patients, incidences of major bleeding of 4–7.5% in
6 months during treatment with low-molecular-weight hep-
arins or oral anticoagulants have been reported [14,19]. The
overall incidences of VT in the ﬁrst half year in our study
do not exceed this risk of major bleeding. However, for
patients with distant metastases at diagnosis the incidence of
VT exceeds the incidence of 40/1000/6 months for testicular,
uterus, and pancreatic cancer. For these types of cancer,
prophylactic treatment might be beneﬁcial. Knowing that
our risk estimates are underestimations, especially for
cancers with a poor prognosis, we believe that patients
with other types of cancer also could beneﬁt from prophy-
lactic anticoagulant treatment. Prophylactic anticoagulant
treatment for these patients should be studied in clinical
trials.
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